Relief Therapeutics Holding AG (RLFTF)

[cjstocksup]

RLFTF HUGE Positive data results:
Results: Median patient follow-up time is 21 days. So far, 19 of 21 patients have survived. One death was due to COVID-related multisystem organ failure and the other to an underlying and unrelated encephalopathy. Improved radiographic appearance of typical “ground glass” COVID-19 features to varying degrees is seen in both lungs of 17 patients and in one lung of 2 patients.. A mean 292% increase in PaO2:FiO2 ratio was seen during the time patients were on ventilation. Improvement in blood oxygenation is seen in all patients, with complete remission from respiratory failure in 9 patients and ongoing improvement in 10. Seven patients were discharged from the hospital, 7 have been sent to intermediate acute care, and 5 require ongoing intensive care. Three of 5 patients on extracorporeal membrane oxygenation (ECMO) prior to treatment with VIP have been decannulated and two have been discharged to home. A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen with corresponding decrease in C-reactive protein. A median 4 point reduction in the NIAID Ordinal Scale was observed (P<.01).

Comment: The short term outcomes in these 21 patients represent a dramatic response in patients who are excluded from all other trials of COVID therapeutics. Improvement in radiographic appearance, oxygenation requirement, and
inflammatory markers is consistent with in vitro evidence of direct anti-viral effect. A phase 2/3 placebo-controlled
trial in patients with Critical COVID-19 and respiratory failure is ongoing.


https://cdn.fbsbx.com/v/t59.2708-21/117307139_226766902013584_1138053463694780524_n.pdf/JG-Youssef-VIP-in-treatment-of-Critical-COVID-19.pdf?_nc_cat=107&_nc_sid=0cab14&_nc_ohc=SXm3Ufr75vYAX97n_kZ&_nc_ht=cdn.fbsbx.com&oh=c7f60686d6a909e2e8d56e76daa1d314&oe=5F3EE7C8&dl=1 .